Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Soleno Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Gilead Sciences, Inc. and Soleno Therapeutics, Inc. present a fascinating study in contrasts over the past decade. From 2014 to 2023, Gilead's SG&A expenses have surged by over 100%, reaching approximately $6 billion in 2023. In contrast, Soleno's expenses have grown by about 360%, yet they remain a fraction of Gilead's, peaking at around $13 million in the same year.

A Decade of Financial Strategy

Gilead's consistent increase in SG&A expenses reflects its expansive growth strategy, while Soleno's more modest rise suggests a focus on lean operations. This divergence highlights the different paths companies can take in managing operational costs, with Gilead investing heavily in market expansion and Soleno maintaining a tighter budget to optimize its resources.